May 3, 2018 / 1:09 PM / 7 months ago

BRIEF-Teva Pharm comments from conference call post-Q1 results

May 3 (Reuters) - Teva Pharmaceutical Industries Ltd :

* TEVA PHARM CEO SCHULTZ: STILL EXPECT TO SELL $4 BILLION WORTH OF GENERIC DRUGS IN U.S. IN 2018

* TEVA PHARM CEO SCHULTZ: MIGRAINE DRUG LIKELY TO BE APPROVED FOR QUARTERLY DOSAGE

* TEVA PHARM CEO SCHULTZ: NO PLANS TO ISSUE NEW EQUITY, NO PLANS FOR M&A ACTIVITY

* TEVA PHARM: DEVELOPING PEN DEVICE FOR MIGRAINE DRUG BUT NO SPECIFIC DATE FOR LAUNCH

* TEVA PHARM CFO: EXPECTS TO PAY DOWN ANOTHER $1.3-$1.5 BILLION OF DEBT IN 2018

* TEVA PHARM: NO EXPECTATION FOR ANOTHER 40 MG GENERIC VERSION OF COPAXONE IN 2018 Further company coverage: (Reporting by Steven Scheer and Tova Cohen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below